Ionis Pharmaceuticals Inc. announced that it has earned $28 million from AstraZeneca following AstraZeneca's completion of IND-supporting studies and license of IONIS-KRAS-2.5, or AZD4785. IONIS-KRAS-2.5x is a Generation 2.5 antisense drug discovered by Ionis designed to directly target KRAS, one of the most frequently mutated genes in cancer.
MaxCyte Inc. and Washington University in St. Louis announced a collaboration to develop unique immunotherapy drug candidates based on MaxCyte's proprietary cell engineering platform technology, CARMA.
MD Anderson and German-based Affimed N.V., announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell product.
Gradalis Inc. and the Icahn School of Medicine at Mount Sinai established a research alliance to advance the scientific understanding of the Gradalis Vigil Engineered Autologous Tumor Cell therapy.
Phylogica Ltd. said Genentech has extended its exclusivity period for the research collaboration and license agreement to discover novel antibiotics utilizing Phylogica's Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.
Senhwa Biosciences Inc. of Taipei and San Diego received the orphan drug designation to CX-4945 for the treatment of cholangiocarcinoma.
The American Joint Committee on Cancer has incorporated the Oncotype DX test in its recently published Eighth Edition AJCC Cancer Staging Manual.
FDA granted an accelerated approval to rucaparib (Rubraca) for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
MERCK announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of Keytruda (pembrolizumab) for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations.
VERASTEM INC. and Infinity Pharmaceuticals Inc. entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. Duvelisib is an investigational, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes that are known to help support the growth and survival of malignant B cells... […]
